Advertisement
Product › Details
Zalmoxis®
Next higher product group | cell therapy product_oo | |
Status | 2016-06-24 registration pending | |
Status | 2019-10-09 sales end–negat | |
Organisation | MolMed S.p.A. (MLMD.MI) | |
Group | Asahi Glass (AGC) (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for cell therapy product_oo
- [1] Bone Therapeutics S.A.. (4/29/22). "Press Release: Bone Therapeutics Announces 2021 Full Year Results". Mont-Saint-Guibert....
- [2] Bone Therapeutics S.A.. (4/12/22). "Press Release: Bone Therapeutics Secures EUR 5 Million Financing [Not for US, AU, CA, et al.]". Mont-Saint-Guibert....
- [3] Bone Therapeutics S.A.. (3/29/22). "Press Release: Bone Therapeutics to Strategically Focus on Lead Cell Therapy Product ALLOB". Mont-Saint-Guibert....
- [4] Bone Therapeutics S.A.. (10/5/20). "Press Release: Bone Therapeutics, Link Health and Pregene to Develop and Commercialize the ALLOB Allogeneic Bone Cell Therapy Platform in China and Southeast Asia". Gosselies....
- [5] MolMed S.p.A.. (3/9/20). "Press Release: The Board of Directors Approved the 2019 Full Year Financial Results". Milan....
- [6] Celyad S.A.. (3/23/17). "Press Release: Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017". Mont-Saint-Guibert....
- [7] MolMed S.p.A.. (2/7/17). "Press Release: MolMed and TTY Biopharm Entered into a Term Sheet to Commercialise Zalmoxis in certain Asian Territories". Milan....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top